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trend is associated with
chronic lung disability.
• Angiopoietin-2 may
play an important path-
ogenic role in patients
with COVID-19, and it
could be a target for
new treatments.
This study examined the association between dynamic angiopoietin-2 assessment and
COVID-19 short- and long-term clinical course. We included consecutive hospitalized
patients from 1 February to 31 May 2020 with laboratory-confirmed COVID-19 from 2
Italian tertiary referral centers (derivation cohort, n5 187 patients; validation cohort, n
5 62 patients). Serum biomarker levels were measured by sandwich enzyme-linked
immunosorbent assay. Lung tissue from 9 patients was stained for angiopoietin-2, Tie2,
CD68, and CD34. Cox model was used to identify risk factors for mortality and
nonresolving pulmonary condition. Area under the receiver operating characteristic
curve (AUROC) was used to assess the accuracy of 3- and 10-day angiopoietin-2 for in-
hospital mortality and nonresolving pulmonary condition, respectively. Three-day
angiopoietin-2 increase of at least twofold from baseline was significantly associated
with in-hospital mortality by multivariate analysis (hazard ratio [HR], 6.69; 95%
confidence interval [CI], 1.85-24.19; P 5 .004) with AUROC 5 0.845 (95% CI, 0.725-0.940).
Ten-day angiopoietin-2 of at least twofold from baseline was instead significantly
associated with nonresolving pulmonary condition by multivariate analysis (HR, 5.33;
95% CI, 1.34-11.77; P # .0001) with AUROC 5 0.969 (95% CI, 0.919-1.000). Patients with
persistent elevation of 10-day angiopoietin-2 levels showed severe reticular interstitial
thickening and fibrous changes on follow-up computed tomography scans.
Angiopoietin-2 and Tie2 were diffusely colocalized in small-vessel endothelia and
alveolar new vessels and macrophages. Angiopoietin-2 course is strongly associated
with COVID-19 in-hospital mortality and nonresolving pulmonary condition.
Angiopoietin-2 may be an early and useful predictor of COVID-19 clinical course, and it
could be a relevant part of disease pathogenesis. Angiopoietin-2 blockade may be
a COVID-19 treatment option.
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February 2021. DOI 10.1182/bloodadvances.2020003736.
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Introduction
Pneumonia associated with SARS-CoV-2 is a life-threatening
condition characterized by diffuse alveolar damage, with the
formation of hyaline membranes and interstitial thickening. Histo-
logic autopsy data from the severe acute respiratory syndrome
epidemic in 2003 showed varying degrees of exudative- and
proliferative-phase acute lung injury, as indicated by the presence of
edema, inflammatory infiltrates, pneumocyte hyperplasia, and
fibrinous exudates. Presentations had in common the presence of
vascular fibrin thrombi, often associated with pulmonary infarcts,
and vascular endothelial damage in small and medium pulmonary
vessels.1
Recently, Ackermann et al2 reported similar pulmonary findings from
an autopsy series of 7 patients who died of COVID-19 pneumonia.
Apart from the expected pathologic findings, the authors reported
severe endothelial injury associated with the intracellular presence
of the virus, with intravascular fibrin deposition, edema, and red
blood cell extravasation in areas of diffuse acute alveolar damage.2
These aspects are shared with acute respiratory distress syndrome
(ARDS), a highly fatal condition that is associated in many cases
with severe virus- and sepsis-associated pneumonia.
Angiopoietins are endothelium-derived angiogenic factors with
potent effects on the vascular endothelium.3,4 The binding of
angiopoietin-2 to its tyrosine kinase with immunoglobulin-like and
Epidermal Growth Factor–like domains 1 (Tie2) receptor is
associated with impairment of vessel integrity, and it enhances
endothelial inflammation.5,6 Interestingly, the angiopoietin-2/1 ratio
and circulating levels of angiopoietin-2 have been shown to be
closely related to prognosis of patients with ARDS.7
The purpose of this study was to correlate the dynamic course of
angiopoietin-2 with in-hospital mortality and nonresolving pulmonary
condition in COVID-19. The hypothesis was that the rapid increase
in circulating angiopoietin-2 levels could be associated with in-
hospital mortality and that its persistent elevation could be a risk
factor for chronic lung function disability.
Methods
Patients
The demographic, clinical, and biochemical characteristic of all
consecutive patients admitted with COVID-19 to the Units of
Medicine and Intensive Care of the Ospedale Civile Baggiovara and
Policlinico, AOU Modena, Modena, Italy, between 1 March and 31
May 2020 (derivation cohort), were studied. COVID-19 infection
was confirmed by nasopharyngeal swab reverse-transcriptase
polymerase chain reaction assay positivity. Depending on their
clinical conditions, patients were admitted to the internal medicine
(n5 71), subintensive care (n5 70), or intensive care unit (n5 46).
Patients showing clinical deterioration (ie, ARDS onset, defined as
acute-onset hypoxemia [partial pressure of arterial blood oxygen
(PaO2)/fraction of inspired air consisting of oxygen (FiO2) ratio ,
300]) with bilateral pulmonary opacities evident on chest imaging
were transferred to the subintensive or intensive care unit.
Coexisting conditions (eg, chronic obstructive pulmonary disease,
history of hypertension, diabetes mellitus, hyperlipidemia, underlying
cardiovascular disease, immunologic or immunosuppressed condi-
tion) were identified from existing physician documentation. The
patients were treated according to the standard of care at the time
of admission (ie, hydroxychloroquine, with enoxaparin and/or
tocilizumab in some subgroups). After discharge, patients were
followed up for clinical and biochemical evaluation on a monthly
basis or more frequently depending on clinical conditions. Non-
resolving pulmonary condition was defined as PaO2/FiO2 ratio
lower than 300 at months 1 and 3 of follow-up and/or abnormal
chest computed tomography (CT) scan.
A consecutive series of patients admitted to the Division of
Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo,
Pavia, Italy, between 1 March and 15 May 2020, was used as an
external cohort for validation of the prognostic scores. The same
demographic, clinical, and biochemical characteristics as in the
derivation cohort were collected.
The study protocol was approved by the Area Vasta Emilia Nord
ethics committee (535/2020/OSS/AOUMO).
Data collection and analysis
Blood samples were prospectively obtained daily for the first 3 days
after admission and every second day thereafter. White blood cell
counts and D-dimer, C-reactive protein (CRP), serum creatinine,
bilirubin, aminotransferase, and lactate dehydrogenase levels from
patients of the derivation and validation cohorts were measured
using routine techniques at admission and subsequently, as
indicated by their clinical conditions. In cases of clinical de-
terioration and transfer to the intensive care unit, daily blood
sampling was resumed.
Sandwich enzyme-linked immunosorbent assay. The
angiopoietin-1, angiopoietin-2, Tie2, Endoglin, von Willebrand
factor (vWF), and interleukin (IL)-6 levels were measured in serum
samples by sandwich enzyme-linked immunosorbent assay using
the respective kits’ reagents and protocols (R&D Systems,
Minneapolis, MN). The baseline levels were evaluated at the
first day of admission in each patient. The dynamic course of
angiopoietin-2 and IL-6 levels after admission (3-day course) was
categorized at 3 days as an increase of at least twofold from
baseline throughout the first 3 days or no increase. The dynamic
course of angiopoietin-2 and IL-6 levels at 10 days after admission
(10-day course) was categorized as an increase of at least twofold
from baseline maintained throughout the 10-day period or no
increase.
Immunohistochemistry. Formalin-fixed paraffin-embedded
samples from postmortem lung tissue from 9 patients were
subjected to routine histologic and immunohistochemical analysis
for angiopoietin-2, Tie2, CD68, and CD34. Briefly, after deparaffi-
nization and rehydration, antigen unmasking was performed with
1 mM EDTA buffer, pH 8, at 98°C for 15 minutes. The sections were
then incubated in methanol 5% and H2O2 1% for 5 minutes for
blocking endogenous peroxidases; nonspecific sites were blocked
using a blocking solution reagent with bovine serum albumin 3% for
30 minutes at room temperature. Sections were then incubated
with goat anti-ANGPT2 (AF623; R&D Systems) primary antibody at
working dilution of 1:50, or with goat anti-Tie2 (AF313; R&D
Systems) primary antibody at working dilution of 1:150, both at 4°C
overnight in humidity chamber, or with prediluted CD34 (clone
QBEnd-10; Roche-Ventana) or CD68 (clone PG-M1; Roche-
Ventana) primary antibodies. Sections were then incubated with
prediluted OmniMap anti-goat horseradish peroxidase conjugated
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secondary antibody (Ventana Medical Systems, Tucson, AZ), for
20 minutes in humidity chamber and then with detection kit
reagents (ultra-view universal horseradish peroxidase multimer and
diaminobenzidine [DAB] chromogen, Ventana Medical Systems)
following the manufacturer’s instructions. The sections were then
counterstained with hematoxylin, dehydrated, and permanently
mounted for microscopic examination. Images of stained liver tissue
were processed with ImageJ software (http://rsbweb.nih.gov/) to
obtain the intensity value of DAB signal.
To verify an ANGPT2 and Tie2 colocalization, we merged 2
consecutive sections stained, respectively, with antibody goat anti-
ANGPT2 (AF623) and goat anti-Tie2 (AF313) after artificial
conversion of brown DAB staining. Briefly, for each section, we
acquired the images of DAB immunostaining on the same region of
interest at the same magnifications (203 and 633). The brown
DAB signal was converted with Adobe Photoshop into a different
color to subsequently perform a merge (ANGPT2 signal into blue
color, Tie2 signal into red color).
Imaging. All chest CT scans were performed during single full
inspiratory breath hold in the supine position on a 128-slice CT
scanner (GE Lightspeed VC, GE Healthcare). The technical
average parameters for the scan were as follows: tube voltage,
120 kV; slice thickness, 2.5 mm; collimation width, 1.25. The
scanner automatically adjusted the tube current modulation based
on the scout image to administer an adequate dose amount.
Nonresolving pulmonary condition was defined as pO2/FiO2 ratio
lower than 300 at 1 and 3 months of follow-up and/or chest CT
scan demonstrating persistence of abnormal lung appearance,
such as airspace opacity and/or presence of reticular shadows.
Statistical analysis
Dichotomous and continuous variables were compared using
Fisher’s exact test and the nonparametric Mann-Whitney U test,
respectively. Strength of the association between circulating bio-
markers was determined by the Pearson correlation coefficient. The
Kaplan-Meier method was used to estimate the cumulative probability
of overall survival. Patient data were censored at the time of death,
discharge, or the end of the study period (31May 2020). Differences in
observed probability were assessed using the log-rank test.
The Cox proportional hazards model was used to identify risk
factors for in-hospital mortality and nonresolving pulmonary
condition. Candidate risk factors for in-hospital mortality were sex,
age, presence of comorbidities, and treatment applied; PaO2/FiO2
ratio and international normalized ratio; platelet count; bilirubin,
CRP, and D-dimer levels; and angiopoietin-2, endoglin, Tie2, and IL-
6 3-day course. For nonresolving pulmonary condition, a 3-day
course of angiopoietin-2 and IL-6 was substituted with a 10-day
course. Variables with P # .10 in the univariate analyses were
included in the final multivariate model.
The accuracy of risk factors for in-hospital mortality and chronic lung
disability, respectively, was assessed by the area under the receiver
operating characteristic curve (AUROC). Validation was performed
by comparing the AUROC of the derivation and validation cohorts.
Predictive Analytics SoftWare statistics (version 26; IBM Corpora-
tion, Armonk, NY) were used for the statistical analyses. P , .05
was considered to indicate statistical significance.
Results
Demographic, clinical, and imaging characteristics
The derivation and validation cohorts comprised 187 and 62
patients, respectively. Their demographic and clinical character-
istics are shown in supplemental Table 1.
The only difference observed between the 2 cohorts was in the
therapeutic regimen administered. For all but 4 (2.1%) patients of
the derivation cohort who received only supportive care, treatment
was started at admission. All patients received hydroxychloroquine
as a single agent in 28 (15.0%) patients or in association with other
agents in the remaining patients: with enoxaparin in 75 (40.1%)
patients, with enoxaparin and tocilizumab in 55 (29.4%) patients,
and with darunavir/cobicistat in 15 (8.0%) patients. Ten patients
(5.34%) received intravenous steroids only (supplemental Table 1).
Thirty-two (17.1%) patients also received intravenous steroids
Table 1. Circulating levels of angiopoietin-1, angiopoietin-2, Tie2, vWF, and endoglin in patients who were survivors and nonsurvivors of
COVID-19
Biomarkers Status
Derivation cohort Validation cohort
Mean Standard deviation P Mean Standard deviation P
Angiopoietin-1, pg/mL Nonsurvivor 20.083 7.168 .882 16.518 12.243 .914
Survivor 19.148 11.520 17.078 12.243
Angiopoietin-2, pg/mL Nonsurvivor 2.765 2.455 .246 1.808 0.879 .424
Survivor 2.125 1.855 2.156 1.628
Angiopoietin-2/angiopoietin-1 Nonsurvivor 0.383 0.210 .007 0.298 0.260 .040
Survivor 0.084 0.015 0.159 0.128
Tie2, pg/mL Nonsurvivor 18.608 7.830 .883 19.803 8.987 .766
Survivor 19.772 9.169 20.518 7.732
vWF, ng/mL Nonsurvivor 283.7 17.5 .395 NA NA NA
Survivor 266.4 40.1 NA NA NA
Endoglin, pg/mL Nonsurvivor 2.535 689 .660 2.533 788 .293
Survivor 1.937 447 2.284 783
NA, not available.
























































































































































 http://ashpublications.org/bloodadvances/article-pdf/5/3/662/1798708/advancesadv2020003736.pdf by guest on 23 July 2021
(associated with only hydroxychloroquine in 6 [3.2%] patients,
with hydroxychloroquine and enoxaparin in 9 [4.8%] patients,
with hydroxychloroquine, enoxaparin, and tocilizumab in 7 [3.7%]
patients).
Fifty-four (28.9%) patients in the derivation cohort underwent CT
examination at admission. Twenty-eight (51.8%) patients under-
went follow-up CT examinations because of nonresolution of
respiratory conditions or suspicion of thromboembolism or when
clinically indicated.
In-hospital mortality
As of 31 May 2020, 53 patients (28.3%) in the derivation cohort
and 18 patients (29.0%) in the validation cohort died.
The baseline levels of circulating angiopoietin-1, angiopoietin-2,
Tie2, vWF, endoglin, and IL-6 did not significantly differ between
COVID-19 survivors and nonsurvivors both in the derivation and
validation cohorts (Table 1). By contrast, the angiopoietin-2/
angiopoietin-1 ratio differed significantly (P 5 .007) between
survivors (0.084 6 0.015) and nonsurvivors (0.383 6 0.210) both
in the derivation and validation cohorts (survivors: 0.159 6 0.128;
nonsurvivors: 0.298 6 0.260, P 5 .040). In the derivation cohort,
the angiopoietin-2/angiopoietin-1 ratio differed significantly (P 5
.007) between survivors (0.084 6 0.015) and nonsurvivors (0.383
6 0.210). Similar results were observed in the validation cohorts
(survivors: 0.1596 0.128; nonsurvivors: 0.2986 0.260, P5 .040).
In the derivation cohort, angiopoietin-2 (–0.398 [P 5 .001]) and
Tie2 (–0.299 [P 5 .041]) were significantly related to the PaO2/
FiO2 ratio, whereas IL-6 levels (–0.199 [P 5 .626]) and
angiopoietin-1 (–0.137 [P 5 .705) did not. The circulating
angiopoietin-2, but not angiopoietin-1, level was strongly related
to the circulating Tie2 level (derivation cohort: r 5 .424, P 5 .028;
validation cohort: r 5 .294; P 5 .026). Hematocrit levels were not
related with circulating angiopoietin-2. However, patients who had
increased angiopoietin-2 at day 3 had significantly higher hemat-
ocrit than those with nonincreased angiopoietin-2 (41.2% vs
38.6%, respectively; P 5 .029).
Among nonsurvivors, but not among survivors, the 3-day levels of
angiopoietin-2 were significantly higher than 1-day levels in both
derivation and validation cohorts, while IL-6 level was not
significantly different between survivors and nonsurvivors in both
the derivation and validation cohorts (Figure 1A-D). By contrast, the
3-day course of angiopoietin-2, but not the 3-day course of IL-6,
was significantly associated with in-hospital mortality both in the
derivation and validation cohort (Figure 1E-H).
The 3-day angiopoietin-2 course showed excellent discrimination
for in-hospital mortality (derivation cohort: AUROC 5 0.845; 95%
confidence interval [CI], 0.725-0.940; validation cohort: area under
the curve [AUC] 5 0.949; 95% CI, 0.727-0.970; Figure 2A-B).
Angiopoietin-2/angiopoietin-1 ratio displayed lower accuracy than
the 3-day angiopoietin-2 course for in-hospital mortality (AUC 5
0.660; 95% CI, 0.489-0.831). The accuracy of the 3-day IL-6
course for in-hospital mortality was also low (AUC 5 0.504; 95%
CI, 0.355-0.652; Figure 2C-D, derivation and validation cohorts,
respectively).
Univariate Cox regression analysis identified older age, use of
combined therapies (data not shown), lower platelet levels, and the
3-day angiopoietin-2 course as risk factors for in-hospital mortality.
In the derivation cohort, 3-day angiopoietin-2 course (hazard ratio
[HR], 6.692; 95% CI, 1.852-24.188; P5 .004) and older age (HR,
2.991; 95% CI, 1.052-8.500; P 5 .040) were independent risk
factors for in-hospital mortality by multivariate analysis. In the
validation cohort, 3-day angiopoietin-2 course (HR, 4.447; 95% CI,
1.345-13.777; P 5 .010) was the only independent risk factor for
in-hospital mortality (Table 2).
Nonresolving pulmonary condition
Twenty patients (10.7% of the derivation cohort) showed evidence
of chronic lung disability after a median follow-up of 3 months. All
patients fulfilled the criteria defined in the Methods section for
nonresolving pulmonary condition (ie, PaO2/FiO2 , 300, which was
associated in 15 patients with radiologic abnormalities). Three of
them died 1, 2.5, and 3 months after discharge. Nineteen of these
20 patients (95.0%) had increased angiopoietin-2 levels at 10-day
evaluation. All these patients also had increased angiopoietin-2
at day 3. Patients with elevated 10-day angiopoietin-2 levels had
significantly longer duration of hospitalization than those who had
not (P 5 .013; Figure 3A). IL-6 course was not equally predictive
(Figure 3B). The 10-day angiopoietin-2 course was also significantly
associated with a lower pulmonary function assessed by PaO2/FiO2
at 1 month (233 6 70 mm Hg in patients with stably increased 10-
day angiopoietin-2 levels vs 335 6 100 mm Hg in patients without
increased levels; P 5 .001; Figure 3C).
All patients but 2 with nonresolving pulmonary condition had a plain
lung x-ray, and 10 (75.0%) also had follow-up CT scans after
a median follow-up time of 10 weeks from admission. Patients with
follow-up shorter than 10 weeks (n 5 9) showed persistence of
interstitial pneumonia and of ground glass opacity, whereas those
with longer follow-up (n 5 9) showed initial thickening of the
interlobular and intralobular septa, progressive reticular interstitial
thickening, and fibrous changes (P 5 .020, x2 test; supplemental
Figure 1).
The 10-day angiopoietin-2 course was significantly associated with
a greater probability of developing chronic lung disability (derivation
cohort: P 5 .003; Figure 3E; validation cohort: P 5 .008;
Figure 3F), whereas IL-6 did not (P 5 .870; Figure 3G).
AUROC revealed that the 10-day angiopoietin-2 course but not IL-6
had an excellent discriminative ability for nonresolving pulmonary
condition (derivation cohort: AUC 5 0.969; 95% CI, 0.919-1.000;
validation cohort: AUC5 0.917; 95%CI, 0.837-0.969; Figure 2D-F).
Univariate Cox analysis also revealed that the use of combined
therapies, median baseline PaO2/FiO2 ratio, and 10-day angiopoietin-2
Figure 1. Relationship between angiopoietin-2 and IL-6 and in-hospital mortality in the derivation and validation cohorts in patients with COVID-19. Day 1
(blue columns) and day 3 (red columns) angiopoietin-2 levels according to survivors and nonsurvivors in the derivation (A) and validation (B) cohorts. Day 1 (blue columns)
and day 3 (red columns) IL-6 levels according to survivors and nonsurvivors in the derivation (C) and validation (D) cohorts. In-hospital mortality according to 3-day course of
angiopoietin-2 in the derivation (E) and validation (F) cohorts. In-hospital mortality according to 3-day course of IL-6 in the derivation (G) and validation (H) cohorts. Red line,
increase of at least twofold from baseline; blue line, no increase.
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Figure 2. ROC curves of angiopoietin-2 and IL-6 courses for in-hospital mortality and nonresolving pulmonary condition in patients with COVID-19. Three-day
course for in-hospital mortality of angiopoietin-2 in the (A) derivation and (B) validation cohorts. Three-day course for in-hospital mortality of IL-6 in the (C) derivation and (D)
validation cohorts. Ten-day course for nonresolving pulmonary condition of angiopoietin-2 in the (E) derivation and (F) validation cohorts. Ten-day course for nonresolving
pulmonary condition of IL-6 in the (G) derivation and (H) validation cohorts.
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course were associated with nonresolving pulmonary condition
(Table 3). In both derivation (HR, 6.861; 95% CI, 1.342-11.769;
P 5 .001) and validation cohorts (HR, 3.085; 95% CI, 1.138-8.363;
P5 .027), 10-day angiopoietin-2 course was the only independent risk




The histologic features of lung tissues from 9 patients with COVID-
19 were consistent with various stages of diffuse alveolar disease,
depending on the time since disease onset. In all patients, the
damage (exudative and/or reparative) involved 50% to 100% of
both lungs. Morphologic alterations observed in the acute exuda-
tive phase were edema, hemorrhage, and hyaline membrane
development in alveolar spaces. In the subacute proliferative phase,
the predominant feature consisted of multiple foci of fibroblastic
proliferation with many thin bands of fibrotic tissue. In the advanced
proliferative phase, areas of dense fibrosis were observed (Figure 4A).
Staining indicated the diffuse presence of angiopoietin-2 and Tie2
in the endothelia of small vessels in portions of lung with less severe
disease, in newly formed vessels in the alveolar walls (immunore-
activity was stronger for Tie2), in pericytes, and in macrophages
inside alveolar spaces (supplemental Figure 2). Desquamating
alveolar cells did not show the same unequivocal immunoreactivity
(Figure 4B). Angiopoietin-2 and Tie2 colocalized in all these
structures (Figure 4B-C). CD68-positive activated macrophages
surrounding the altered alveola, and the abundant CD34-positive
new vessels in the alveolar wall were also reactive for angiopoietin-2
and Tie2 (Figure 4D).
Discussion
In a cohort of Caucasian patients with COVID-19, we demonstrated
that circulating 3- and 10-day angiopoietin-2 courses can early and
accurately assess the risk for in-hospital mortality and nonresolving
pulmonary condition, respectively. To the best of our knowledge,
this is the first study demonstrating that a single simple biomarker
(ie, 10-day angiopoietin-2 course) is able to predict chronic lung
disability. The robustness of these results was confirmed in an
external validation cohort. Circulating angiopoietin-2 course and
older age were the only 2 independent risk factors for in-hospital
death, as shown by multivariate analysis. External validation of this
model showed good accuracy. From a clinical point of view, 3-day
angiopoietin-2 course could help physicians to improve the
allocation of medical resources, potentially reducing the over-
crowding that we have witnessed in health care systems, which
significantly impacted mortality worldwide during the COVID-19
pandemic. Although baseline angiopoietin-2 level has been shown
to predict mortality in patients with non–COVID-19-ARDS7 and
intensive care unit admission in patients with COVID-19,8 we did
not find such association at baseline among patients with COVID-
19, likely because the baseline value resents the individual
heterogeneity of patients at presentation. We did find, however,
that the dynamic 3-day angiopoietin-2 course, blunting the
heterogeneity of the stage of disease at admission, was an early,
strong, and independent risk factor for COVID-19 mortality.
Interestingly, Pine et al9 provided further evidence that angiopoietin-
2 levels at intensive care unit admission were elevated in patients with
critical COVID-19, strongly predicting in-hospital mortality. All these
data may prove useful to guide novel therapeutic strategies, including
those that protect the endothelium.
Results of our analyses confirmed previous reports from China and
the United States,10-12 showing older age as a significant risk factor
for in-hospital death in COVID-19. However, in-hospital mortality in
our study was higher than that observed in other studies conducted
both within and outside China.10,11 A possible reason could be
because of the very high proportion of elderly people in Italy, the
highest in Europe.13 Not surprisingly, the median age in our cohort
was 69 years, which is higher than that observed in other studies.
The 10-day angiopoietin-2 course showed a similarly strong
predictive power for chronic lung disability. The predictive power
of angiopoietin-2 for in-hospital mortality and chronic lung disability
is not surprising, given that modifications in the angiopoietin-2 level
Table 2. Early prediction of in-hospital mortality was analyzed by Cox
regression analysis (derivation and validation cohorts)
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Derivation cohort
Sex* 0.673 (0.336-1.345) .262
Age, y 1.027 (1.004-1.051) .019 2.991 (1.052-8.500) .040
Comorbidity (yes/no) 0.431 (0.153-1.212) .111
Therapy† 0.467 (0.239-0.914) .026 0.660 (0.239-1.818) .421
PaO2/FIO2‡ 0.998 (0.995-1.001) .267
INR‡ 0.980 (0.926-1.037) .483
Bilirubin‡ 0.921 (0.731-1.162) .488
CRP‡ 1.022 (0.993-1.052) .142
Platelets‡ 0.417 (0.233-0.746) .003 0.805 (0.293-2.216) .675
D-dimer‡ 1.667 (0.839 23.314) .145
vWF 1.255 (0.078-20.147) .873
IL-6§ 1.158 (0.464-2.915) .755
Endoglin§ 1.366 (0.085-2.084) .825
Angiopoietin-2§ 5.502 (1.558-19.431) .008 6.692 (1.852-24.188) .004
Tie2§,|| 2.724 (1.008-7,352) .048
Validation cohort
Sex* 0.653 (0.188-2.270) .502
Age, y 2.631 (0.983-7.040) .054 2.146 (0.782-5.893) .138
Comorbidity (yes/no) 0.553 (0.193-1.581) .269
Therapy† 0.655 (0.362-1.183) .160
PaO2/FIO2‡ 0.996 (0.991-1.002) .216
Platelets‡ 1.292 (0.508-3.283) .591
D-dimer‡ 0.012 (0.000-17.869) .236
IL-6§ 1.544 (0.472-5.055) .473
Endoglin§ 1.059 (0.402-2.784) .908
Angiopoietin-2§ 4.592 (1.473-14.317) .009 4.447 (1.435-13.777) .010
Tie2§,|| 3.223 (1.112-9.341) .031
INR, international normalized ratio.
*Female reference.
†Hydroxychloroquine 1 enoxaparin 1 tocilizumab vs other regimens (reference).
‡Values above median vs below median.
§Three-day course.
||Tie2 was not included in multivariate analysis, being colinear with angiopoietin-2.
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Figure 3. Outcomes according to 10-day angiopoietin-2 and IL-6 course. Length of hospitalization according to 10-day angiopoietin-2 (A) and IL-6 (B) courses.
PaO2/FiO2 ratio levels at 1 month according to 10-day angopoietin-2 (C) and IL-6 (D) courses. Cumulative incidence of nonresolving pulmonary condition according to 10-day
angiopoietin-2 course in derivation (E) and validation (F) cohorts. Cumulative incidence of nonresolving pulmonary condition according to 10-day IL-6 course in derivation
(G) and validation (H) cohorts. Red line, increase of at least twofold from baseline; blue line, no increase.
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may be a relevant part of disease pathogenesis. Recently,
Ackermann et al2 showed that pulmonary vascular endothelialitis
and angiogenesis are distinctive COVID-19 features, with affected
patients showing almost 3 times more new vessel growth in the
lungs than do patients with influenza. Our findings reflect maximal
activation of the angiopoietin-2/Tie2 system in patients with COVID-
19, as shown by extremely high circulating levels and hyperintense
staining in the lungs, with constant colocalization with CD34
demonstrating the hyperactivation of neoangiogenesis.
The angiopoietin-1/angiopoietin-2/Tie2 system is known to be
extremely important in physiologic and pathologic blood vessel
formation and angiogenesis.14 Several groups have evaluated
endothelial damage in ARDS, identifying the angiopoietin-Tie2
pathway as a prognostic factor.7,15,16 Angiopoietins are
endothelium-derived angiogenic factors with potent effects on the
vascular endothelium.3,4 They interact with their receptor, Tie2,
which is expressed on the luminal endothelium. Angiopoietin-1 and
angiopoietin-2 are antagonist ligands that bind with similar affinity to
Tie2. Angiopoietin-1/Tie2 signaling maintains vessel integrity,
inhibits vascular leakage, and suppresses inflammatory gene
expression.3,4 The binding of angiopoietin-2 to Tie2 interferes with
this protective role and facilitates endothelial inflammation.5,6
Endothelial damage associated with inflammation and hypoxia
stimulates the exocytosis of endothelial Weibel-Palade bodies and
the rapid release of angiopoietin-2.5,17 High angiopoietin-2 levels
directly activate Tie2, enhancing endothelial cell survival through the
phosphatidylinositol 39-kinase/Akt signal transduction pathway.18
Tie2 is expressed almost exclusively by endothelial cells, with the
greatest expression in the lung and liver under normal conditions.19
In pathologic conditions, especially those with inflammatory back-
grounds (as in the experimental asthma model established with
ovalbumin-sensitized and ovalbumin-challenged mice),14 Tie2 is
expressed abundantly in airway epithelial cells and in a subset of
macrophages in addition to its constitutive expression in pulmonary
vessels. Consistently, we observed enhanced Tie2 expression not
only in pulmonary vessels, but also in the bronchial epithelial cells
and macrophages, in patients with COVID-19. This expression was
associated with strong angiopoietin-2 expression in the lungs,
extremely high circulating angiopoietin-2 levels, and significantly
increased angiopoietin-2/1 ratios. This combination of factors has
been associated with extensive airway remodeling, including
epithelial cell shedding, subepithelial fibrosis, smooth muscle cell
hyperplasia, edema, and angiogenesis,14 and appears to form the
pathologic basis for acutely progressive respiratory distress in
patients with COVID-19. Further evidence supported by our
observations is that patients with persistently elevated angiopoietin-
2 and Tie2 levels rapidly developed a nonresolving pulmonary
condition, as reflected by significantly lower follow-up PaO2/FiO2
ratios and follow-up CT findings in comparison with recovering
patients with normalized angiopoietin-2 levels.
The slope of circulating angiopoietin-2 level elevation is of particular
relevance. Angiopoietin-2 is stored in the Weibel-Palade bodies in
the cytoplasm of endothelial cells. It can be released within minutes
after stimulation, as in rapid vascular homeostatic reactions
triggered by inflammation and coagulation.5,17 In the chain of
events after angiopoietin-2 release, neoangiogenesis is a key factor.
This neoangiogenic reaction, in turn, increases inflammation,
starting a vicious cycle of angiogenesis–inflammation–angiogene-
sis associated with the formation of defective capillaries, suscep-
tibility to microthrombosis, and increased vascular permeability.
Consistently, Parikh et al20 identified in non–COVID-19 patients
excess serum angiopoietin-2 as a critical factor favoring the
disruption of pulmonary endothelial function and determining
congestion and pulmonary vascular leakage, which in turn facilitates
the recruitment of immune cells to the lung, where they participate
in the development and persistence of cytokine storms.
All the evidence suggests that angiopoietin-2 blockade is an important
therapeutic option, as the drugs currently used for COVID-19 achieve
low survival benefit. Although this treatment approach has not been
examined in a human study, many methods, including RNA
aptamers,21,22 blocking antibodies and peptides,23 and angiopoieitin-
1 administration24 have been used to block angiopoietin-2 in animal
models. More recently, Lomas-Neira et al25 used the small interfering
RNA inhibition of angiopoietin-2 protein synthesis to block its activity in
an experimental mouse model of ARDS. They observed significant
improvements in the PaO2/FiO2 ratio and inflammation biomarkers,
improving 10-day survival. Several selective angiopoietin-2 inhibitors
are under evaluation in the oncologic setting (NCT03239145,
NCT01004822, NCT01248949), and an antibody against
angiopoietin-2 is already under evaluation in a phase 2 randomized
Table 3. Prediction of nonresolving lung condition was analyzed by
Cox regression analysis (derivation and validation cohorts)
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Derivation cohort
Sex* 1.281 (0.453-3.523) .641
Age, y 0.982 (0.399-2.469) .986
Comorbidity (yes/no) 1.078 (0.358-3.243) .894
Therapy† 2.298 (0.949-5.565) .065 0.870 (0.344-2.203) .769
PaO2/FIO2‡ 0.323 (0.123-0.852) .022 0.856 (0.326-2.248) .752
INR‡ 0.995 (0.972-1.019) .679
Bilirubin ‡ 0.987 (0.934-1.043) .643
CRP‡ 0.585 (0.231-1.482) .258
Platelets ‡ 1.183 (0.233-1.678) .424
D-dimer ‡ 1.183 (0.486-2.879) .711
IL-6§ 1.454 (0.650-3.250) .362
Angiopoietin-2§ 3.264 (2.504-4.028) .001 5.332 (1.342-11.769) .001
Validation cohort
Sex* 0.888 (0.248-3.185) .856
Age, y 0.998 (0.357-2.789) .997
Comorbidity (yes/no) 1.028 (0.269-3.931) .967
Therapy† 2.201 (1.251-3,872) .006 3.437 (1.252-9.340) .017
PaO2/FIO2‡ 0.236 (0.066-0.835) .025 1.847 (0.379-9.000) .447
CRP‡ — —
Platelets‡ 0.698 (0.248-1.969) .497
D-dimer‡ 0.570 (0.570-3.729) .558
IL-6§ — —
Angiopoietin-2§ 2.179 (1.250-5.289) .002 5.250 (2.127-27.809) .001
*Female reference.
†Hydroxychloroquine 1 enoxaparin 1 tocilizumab vs other regimens (reference).
‡Values above median vs below median.
§Ten-day course.
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controlled trial in patients hospitalized with COVID-19 pneu-
monia, who are at higher risk for progression to ARDS.26
Their demonstrated safety and efficacy in the inhibition of
angiopoietin-2 activity warrant the exploration of their efficacy
for COVID-19–induced lung damage.
Our study has some limitations. First, there is a lack of a control
group with similar non–COVID-19 respiratory conditions. How-
ever, it should be underlined that the mechanisms, which we
have described, could not be unique to COVID-19, but











Figure 4. Immunohistochemical analysis of autoptic lung tissue from a patient with COVID-19. (A) Immunostaining for angiopoietin-2 (203): immunohistochemistry
shows immunoreactivity in the endothelia, pneumocytes, and macrophages. Scale bar, 6.7 mm. (B) Immunostaining for Tie2 (203): the same field as in Figure 1. Tie2 showed
the same immunoreactivity observed for angiopoietin-2 immunoreaction. (C) Hematoxylin and eosin staining (203): diffuse alveolar damage in COVID-19, interstitial in-
flammation, and dilated capillaries in the alveolar wall. The alveolar spaces show fibrin and macrophages. (D-F) The brown DAB signal for angiopoietin-2 shown in panel A was
converted into a blue color and that for Tie2 shown in panel B was converted into a red color. The images in panels D and E were merged, resulting in a violet color, where the
angiopoietin-2 and Tie2 colocalize. (G-I) Higher magnification (633) of the inset in panel A highlights angiopoietin2 and tie2 immunoreactivity both in endothelia (red arrow-
heads) and in pneumocytes (yellow arrows). Scale bar, 1.7 mm. (J-L) The brown DAB signal for angiopoietin-2 shown in panel G was converted into a blue color and that for
Tie2 shown in panel H was converted into a red color. The images in panels J and K were merged, resulting in a violet color, where the angiopoietin-2 and Tie2 colocalize.
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implications. Second, treatment regimens were different between
derivation and validation cohort, with a greater propensity to use
enoxaparin in the derivation cohort. This may have resulted in a better
survival for these patients in comparison with those treated with
hydroxychloroquine alone. Differently from enoxaparin, hydroxychlor-
oquine does not have known effects on endothelial function, whereas
the effect of tocilizumab on angiopoietin-2 or other markers of
endothelial function is not really known. In this study, the association
between different treatment regimens and in-hospital mortality was
not confirmed by multivariate analysis, making us confident that
differences in treatments have not affected our results. Third,
retrospective studies have problems that reduce their internal and
external validity and selection bias can lead to incorrect results and
spurious associations. However, we included only consecutive
patients with confirmed COVID-19; therefore, we are confident that
selection bias could not be relevant. Fourth, to overcome the issue of
the generalizability of results to different populations and settings, we
performed an external validation that showed good discrimination
ability, despite the significant difference in the therapeutic approach
between derivation and validation cohorts. Finally, a weakness of our
study is the relatively small sample size, and further data collected in
different clinical settings are needed.
In conclusion, we demonstrated that circulating 3- and 10-day
angiopoietin-2 courses can early and accurately assess the risk for
in-hospital mortality and chronic lung disability in Caucasian
patients with COVID-19. These findings could improve the triage
and management of patients with COVID-19 in different health care
organization settings. The key role played by angiopoietin-2 in
endothelial cell disruption and associated events indicates
angiopoietin-2 as an important part of disease pathogenesis and
a potential target for new specific COVID-19 treatments.
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